Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
Sponsor: Merck Sharp & Dohme LLC
Summary
The goal of the study is to learn what happens to MK-4482 after single and multiple doses in healthy Chinese participants over time. Researchers also want to learn about the safety of MK-4482, including how well people tolerate it.
Official title: An Open-label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of MK-4482 in Chinese Healthy Male Participants
Key Details
Gender
MALE
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2023-06-28
Completion Date
2023-08-05
Last Updated
2026-04-16
Healthy Volunteers
Yes
Conditions
Interventions
MK-4482
Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.
Locations (1)
Peking University Third Hospital (Site 0001)
Beijing, Beijing Municipality, China